The inhibition of Candida albicans secreted aspartyl proteinase by triangular gold nanoparticles

Document Type : Research Paper

Authors

1 Departments of Microbiology, Pars Hospital Lab, Tehran, Iran

2 Department of Genetics, Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

3 Department of Laboratory Sciences, School of Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Abstract

Objective(s):
The aim of this study was to synthesize triangular gold nanoparticles, and then to evaluate their capability for inhibition of Candida albicans secreted aspartyl proteinase 2(Sap2).
Materials and Methods:
To synthesize the nanoparticles, hydrogen tetrachloroaurate and hexadecyl trimethyl ammonium bromide were incubated in presence of Sn(IV) meso-tetra(N-methyl-4-pyridyl) porphine tetratosylate chloride, and then characterized. Next, thirty clinical isolates of Candida albicans were obtained from patients suffering from vaginal candidiasis. Each Candida albicans isolate was first cultured in YCB-BSA medium, incubated for 24 h at 35 ºC. Then, 100 µL of triangular gold nanoparticles at three concentrations (16, 32, and 64 µg/mL) were added to Candida suspension, and incubated for 24 and 48 h at 35 ºC. To evaluate Sap activity, 0.1 mL of medium and 0.4 mL of 0.1 M sodium citrate buffer (pH 3.2) containing BSA 1% w/v were added, and incubated 15 minutes at 37 ºC. Then, the optical density of each tube was read at 280 nm. Enzyme activity was expressed as the amount (µM) of tyrosine equivalents released per min per ml of culture supernatant.

Results:
This study showed that the size of the nanoparticles was 70±50 nm. Sap activity evaluation demonstrated triangular gold nanoparticles could inhibit the enzyme, and the higher incubation time and concentration led to more decrease of Sap activity.
Conclusion:
For the first time, we demonstrated triangular gold nanoparticles as a novel inhibitor of Sap enzyme which may be useful for treatment of candidiasis.
 

Keywords

References

  1. Cafarchia C, Figueredo LA, Coccioli C, Camarda A, Otranto D. Enzymatic activity of Microsporum canis and Trichophyton mentagrophytes from breeding rabbits with and without skin lesions. Mycoses. 2012; 55(1): 45-49.
  2. Reichard U, Cole GT, Ruchel R, Monod M. Molecular cloning and targeted deletion of PEP2 which encodes a novel aspartic proteinase from Aspergillus fumigatus. Int J Med Microbiol. 2000; 290(1): 85-96.
  3. Aoki S, Ito-Kuwa S, Nakamura K, Kato J, Ninomiya K, Vidotto V. Extracellular proteolytic activity of Cryptococcus neoformans. Mycopathologia. 1994; 128(3): 143-150.
  4. De Bernardis F, Sullivan PA, Cassone A. Aspartyl proteinases of Candida albicans and their role in pathogenicity. Med Mycol. 2001; 39(4): 303-313.
  5. Boriollo MF, Bassi RC, dos Santos Nascimento CM, Feliciano LM, Francisco SB, Barros LM, et al. Distribution and hydrolytic enzyme characteristics of Candida albicans strains isolated from diabetic patients and their non-diabetic consorts. Oral Microbiol Immunol. 2009; 24(6): 437-450.
  6. Rajendran R, Robertson DP, Hodge PJ, Lappin DF, Ramage G. Hydrolytic enzyme production is associated with Candida albicans biofilm formation from patients with type 1 diabetes. Mycopathologia. 2010; 170(4): 229-235.
  7. Kalkanci A, Bozdayi G, Biri A, Kustimur S. Distribution of secreted aspartyl proteinases using a polymerase chain reaction assay with SAP specific primers in Candida albicans isolates. Folia microbiologica. 2005; 50(5): 409-413.
  8. Schaller M, Januschke E, Schackert C, Woerle B, Korting HC. Different isoforms of secreted aspartyl proteinases (Sap) are expressed by Candida albicans during oral and cutaneous candidosis in vivo. J Med Microbiol. 2001; 50(8): 743-747.
  9. Magee BB, Hube B, Wright RJ, Sullivan PJ, Magee PT. The genes encoding the secreted aspartyl proteinases of Candida albicans constitute a family with at least three members. Infect Immun. 1993; 61(8): 3240-3243.
  10. Gilfillan GD, Sullivan DJ, Haynes K, Parkinson T, Coleman DC, Gow NA. Candida dubliniensis: phylogeny and putative virulence factors. Microbiology. 1998; 144 ( Pt 4): 829-838.
  11. Zaugg C, Borg-Von Zepelin M, Reichard U, Sanglard D, Monod M. Secreted aspartic proteinase family of Candida tropicalis. Infect Immun. 2001; 69(1): 405-412.
  12. De Viragh PA, Sanglard D, Togni G, Falchetto R, Monod M. Cloning and sequencing of two Candida parapsilosis genes encoding acid proteases. J Gen Microbiol. 1993; 139(2): 335-342.
  13. Rodrigues JA, Hofling JF, Azevedo RA, Gabriel DL, Tamashiro WM. Production of monoclonal antibodies for detection of a secreted aspartyl proteinase from Candida spp. in biologic specimens. Hybridoma (Larchmt). 2007; 26(4): 201-210.
  14. Leto G, Pizzolanti G, Tumminello FM, Gebbia N. Effects of E-64 (cysteine-proteinase inhibitor) and pepstatin (aspartyl-proteinase inhibitor) on metastasis formation in mice with mammary and ovarian tumors. In Vivo. 1994; 8(2): 231-236.
  15. Pichova I, Pavlickova L, Dostal J, Dolejsi E, Hruskova-Heidingsfeldova O, Weber J, et al. Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors. Eur J Biochem. 2001; 268(9): 2669-2677.
  16. Cutfield SM, Dodson EJ, Anderson BF, Moody PC, Marshall CJ, Sullivan PA, et al. The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Structure. 1995; 3(11): 1261-1271.
  17. Tarantola M, Pietuch A, Schneider D, Rother J, Sunnick E, Rosman C, et al. Toxicity of gold-nanoparticles: synergistic effects of shape and surface functionalization on micromotility of epithelial cells. Nanotoxicology. 2011 5(2): 254-268.
  18. Sun Y, Xia Y. Shape-controlled synthesis of gold and silver nanoparticles. Science. 2002; 298(5601): 2176-2179.
  19. Pal S, Tak YK, Song JM. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-negative bacterium Escherichia coli. Appl Environ Microbiol. 2007; 73(6): 1712-1720.
  20. Stoehr LC, Gonzalez E, Stampfl A, Casals E, Duschl A, Puntes V, et al. Shape matters: effects of silver nanospheres and wires on human alveolar epithelial cells. Part Fibre Toxicol. 2011; 8:36. doi:10.1186/1743-8977-8-36.
  21. Miranda A, Malheiro E, Skiba E, Quaresma P, Carvalho PA, Eaton P, et al. One-pot synthesis of triangular gold nanoplates allowing broad and fine tuning of edge length. Nanoscale. 2010; 2(10): 2209-2216.
  22. Rehani S, Rao NN, Rao A, Carnelio S, Ramakrishnaiah SH, Prakash PY. Spectrophotometric analysis of the
    expression of secreted aspartyl proteinases from Candida in leukoplakia and oral squamous cell carcinoma. J Oral Sci. 2011; 53(4): 421-425.
  23. Jebali A, Hajjar FH, Pourdanesh F, Hekmatimoghaddam S, Kazemi B, Masoudi A, et al. Silver and gold nanostructures: antifungal property of different shapes of these nanostructures on Candida species. Med Mycol. 2014; 52(1): 65-72.
  24. Smitha SL, Gopchandran KG. Surface enhanced Raman scattering, antibacterial and antifungal active triangular gold nanoparticles. Spectrochim Acta A Mol Biomol Spectrosc. 2013; 102: 114-119.
  25. Goldman RC, Frost DJ, Capobianco JO, Kadam S, Rasmussen RR, Abad-Zapatero C. Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis. Infect Agents Dis. 1995; 4(4): 228-247.
  26. Cadicamo CD, Mortier J, Wolber G, Hell M, Heinrich IE, Michel D, et al. Design, synthesis, inhibition studies, and molecular modeling of pepstatin analogues addressing different secreted aspartic proteinases of Candida albicans. Biochem Pharmacol. 2013; 85(7): 881-887.

 

Nanomedicine Journal
Volume 2, Issue 1 - Serial Number 1
January 2015
Pages 54-59

Files

Share

How to cite

Statistics